Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolebrutinib PK in Mild Hepatic Impairment
NCT05283915Phase 1Completed
- Sponsor
- Sanofi
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tolebrutinib in multiple sclerosis (MS) (2 arms), sponsored by Sanofi. Primary endpoint: Area Under the Curve. Started Mar 2022; status: completed.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05283915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283915.